• KOL
    • Ulcerative Colitis
    • Geert R A M D'haens
    • Geert R A M D'Haens: Influence Statistics

      Geert R A M D'Haens

      Geert R A M D'Haens

      Show email address

      Department of Gastroenterology, Amsterdam University Medical Centres, Amsterdam, The Netherlands | Department of Gastroenterology and Hepatology, Amsterdam University Medical ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Geert R A M D'Haens:Expert Impact

      Concepts for whichGeert R A M D'Haenshas direct influence:Ulcerative colitis,Crohn disease,Crohns disease,Inflammatory bowel disease,Clinical remission,Mucosal healing,Inflammatory bowel,Surgical closure.

      Geert R A M D'Haens:KOL impact

      Concepts related to the work of other authors for whichfor which Geert R A M D'Haens has influence:Ulcerative colitis,Inflammatory bowel disease,Colorectal cancer,Mucosal healing,Ibd patients,Clinical remission,Monoclonal antibodies.

      KOL Resume for Geert R A M D'Haens

      Year
      2022

      Department of Gastroenterology, Amsterdam University Medical Centres, Amsterdam, The Netherlands

      Alimentiv Inc., London, Ontario, Canada

      2021

      Inflammatory Bowel Disease Centre, Academic Medical Centre, 1105 AZ Amsterdam, Netherlands.

      AmsterdamUMC, Gastroenterology and Hepatology, Amsterdam, The Netherlands

      Alimentiv Inc., London, ON, Canada

      2020

      Alimentiv Inc, London, Ontario, Canada; Department of Gastroenterology and Hepatology, Amsterdam University Medical Centre, Academic Medical Centre, Amsterdam, Netherlands.

      Amsterdam UMC location AMC, Gastroenterology and Hepatology, Amsterdam, The Netherlands

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Geert R A M D'Haens is among the top experts in the world.
      Concept World rank
      histologic remission area #1
      ius poc ius #1
      median ifx iqr #1
      vivo jak1i #1
      50 uc patients #1
      colectomy disease #1
      uc retreatment #1
      resection infliximab #1
      patients closed fistulas #1
      crohns disease activity #1
      etmi afi colour #1
      inflammatory burden patients #1
      intestinal mucosa monitoring #1
      fcp ius #1
      endoscopic response remission #1
      ifx poct #1
      maintenance period hrql #1
      75 μg week #1
      reliability assche #1
      reason absenteeism #1
      48‐week extension study #1
      ibstype symptoms prevalence #1
      current misunderstandings #1
      wp loss #1
      pouchoscopy biopsies #1
      uc improvements #1
      concomitant thiopurines #1
      pregnancy ius #1
      ibd 12 months #1
      benefit infliximab #1
      vedolizumab uc #1
      ius disease activity #1
      perineal wound patient #1
      children atis #1
      macrophages rag1 mice #1
      primary ileocaecal resection #1
      tdm thiopurines #1
      appendectomy disease #1
      ifx atis #1
      adl antibodies #1
      adalimumab escalation #1
      uc leukocyte scintigraphy #1
      fcp pregnancy #1
      ifx median ifx #1
      ifx dbs #1
      cdeis1 #1
      response adalimumab therapy #1
      appendectomy refractory uc #1
      infliximab induction therapy #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Geert R A M D'Haens

      KOL-Index: 21441

      BACKGROUND: Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial. We further evaluated the efficacy of tofacitinib as induction and maintenance therapy.

      METHODS: We conducted three phase 3, randomized, double-blind, placebo-controlled trials of tofacitinib therapy in adults with ulcerative colitis. In the OCTAVE Induction 1 and 2 trials, 598 and 541 patients, respectively, who had ...

      Known for Tofacitinib Placebo | Ulcerative Colitis | Maintenance Therapy | Octave Induction | 8 Weeks
      KOL-Index: 20720

      BACKGROUND: It is important to minimize placebo rates in randomised controlled trials (RCTs) to efficiently detect treatment differences between interventions. Historically, high placebo rates have been observed in clinical trials of ulcerative colitis (UC). A better understanding of factors influencing placebo rates may lead to more informed clinical trial design.

      OBJECTIVES: A systematic review and meta-analysis was conducted to evaluate placebo response and remission rates in RCTs ...

      Known for Placebo Response | Remission Rates | Ulcerative Colitis | Maintenance Therapy | Induction Trials
      KOL-Index: 19976

      BACKGROUND & AIMS: Adalimumab is a fully human monoclonal antibody that binds tumor necrosis factor (TNF)-α. Its efficacy as maintenance therapy for patients with ulcerative colitis has not been studied in a controlled, double-blind trial.

      METHODS: Ulcerative colitis long-term remission and maintenance with adalimumab 2 (ULTRA 2) was a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of adalimumab in induction and maintenance of clinical remission in 494 ...

      Known for Patients Adalimumab | Clinical Remission | Ulcerative Colitis | Week Placebo | Maintenance Therapy
      KOL-Index: 19087

      BACKGROUND: Biomarkers of intestinal inflammation, such as faecal calprotectin and C-reactive protein, have been recommended for monitoring patients with Crohn's disease, but whether their use in treatment decisions improves outcomes is unknown. We aimed to compare endoscopic and clinical outcomes in patients with moderate to severe Crohn's disease who were managed with a tight control algorithm, using clinical symptoms and biomarkers, versus patients managed with a clinical management ...

      Known for Tight Control | Disease Clinical | Patients Crohn | 3 Trial | Primary Endpoint
      KOL-Index: 18543

      BACKGROUND: Treatment of patients with ileocaecal Crohn's disease who have not responded to conventional therapy is commonly scaled up to biological agents, but surgery can also offer excellent short-term and long-term results. We compared laparoscopic ileocaecal resection with infliximab to assess how they affect health-related quality of life.

      METHODS: In this randomised controlled, open-label trial, in 29 teaching hospitals and tertiary care centres in the Netherlands and the UK, ...

      Known for Resection Infliximab | Terminal Ileitis | 12 Months | Laparoscopic Ileocaecal | Conventional Therapy
      KOL-Index: 17741

      BACKGROUND & AIMS: We investigated the efficacy of adalimumab for inducing and maintaining mucosal healing in patients with Crohn's disease (CD).

      METHODS: A randomized, double-blind, placebo-controlled trial (extend the safety and efficacy of adalimumab through endoscopic healing [EXTEND]) evaluated adalimumab for induction and maintenance of mucosal healing in 135 adults with moderate to severe ileocolonic CD. The baseline degree of mucosal ulceration was documented by ileocolonoscopy. ...

      Known for Mucosal Healing | Adalimumab Patients | Extend Trial | Placebo Week | Induction Therapy
      KOL-Index: 16848

      BACKGROUND: Episodic infliximab (IFX) treatment is associated with the formation of antibodies to IFX (ATIs) in the majority of patients, which can lead to infusion reactions and a shorter duration of response. Concomitant use of immunosuppressives (IS) reduces the risk of ATI formation.

      AIMS AND METHODS: To investigate which of the IS-that is, methotrexate (MTX) or azathioprine (AZA)-is most effective at reducing the risk of ATI formation, a multicentre cohort of 174 patients with ...

      Known for Patients Atis | Immunosuppressive Therapy | Aza Mtx | Ifx Formation | Infliximab Infusions
      KOL-Index: 16532

      BACKGROUND & AIMS: There is an increasing need for new treatments for patients with Crohn's disease (CD) in whom previous therapy with tumor necrosis factor (TNF) antagonists has failed. We performed a placebo-controlled, phase 3, double-blind trial to evaluate the efficacy and safety of vedolizumab, an antibody against the integrin α4β7, as induction therapy.

      METHODS: Patients with moderately to severely active CD (CD activity index [CDAI] score, 220-400 points) were assigned randomly ...

      Known for Vedolizumab Patients | Induction Therapy | Tumor Necrosis | Remission Week | Factor Antagonist
      KOL-Index: 16098

      The advent of biological therapy has revolutionized inflammatory bowel disease (IBD) care. Nonetheless, not all patients require biological therapy. Selection of patients depends on clinical characteristics, previous response to other medical therapy, and comorbid conditions. Availability, reimbursement guidelines, and patient preferences guide the choice of first-line biological therapy for luminal Crohn's disease (CD). Infliximab (IFX) has the most extensive clinical trial data, but ...

      Known for Biological Therapy | London Position Statement | Monoclonal Antibodies | Ifx Patients | Loss Response
      KOL-Index: 16004

      BACKGROUND: The comparative efficacy and safety of infliximab and azathioprine therapy alone or in combination for Crohn's disease are unknown.

      METHODS: In this randomized, double-blind trial, we evaluated the efficacy of infliximab monotherapy, azathioprine monotherapy, and the two drugs combined in 508 adults with moderate-to-severe Crohn's disease who had not undergone previous immunosuppressive or biologic therapy. Patients were randomly assigned to receive an intravenous infusion of ...

      Known for Combination Therapy | Infliximab Azathioprine | Drugs Patients | Hormones Adult | Moderatetosevere Crohns Disease
      KOL-Index: 15703

      BACKGROUND: Biological treatment of chronic inflammatory diseases has improved patient outcomes but increased health-care costs. Switching patients from originator infliximab to a biosimilar can reduce costs, but prospective data about pharmacokinetics and potential immunogenicity are scarce. We aimed to show that infliximab serum concentrations with biosimilar CT-P13 are non-inferior to those with originator infliximab after switching from originator infliximab in patients with ...

      Known for Originator Infliximab | Inflammatory Bowel Disease | Ulcerative Colitis | Ctp13 Patients | Switching P13
      KOL-Index: 15323

      BACKGROUND: The interleukin-23 pathway is implicated genetically and biologically in the pathogenesis of Crohn's disease. We aimed to assess the efficacy and safety of risankizumab (BI 655066, Boehringer Ingelheim, Ingelheim, Germany), a humanised monoclonal antibody targeting the p19 subunit of interleukin-23, in patients with moderately-to-severely active Crohn's disease.

      METHODS: In this randomised, double-blind, placebo-controlled phase 2 study, we enrolled patients at 36 referral ...

      Known for Clinical Remission | Crohn Disease | Risankizumab Placebo | Boehringer Ingelheim | Phase 2
      KOL-Index: 15297

      BACKGROUND & AIMS: Mucosal healing might alter midterm and long-term outcomes of patients with Crohn's disease (CD) and has become an important end point in clinical trials. However, the minimal degree of mucosal improvement (endoscopic response) required to alter midterm outcomes is not known. We aimed to determine the best definition of endoscopic response by evaluating data on the Simple Endoscopic Score for Crohn's Disease (SES-CD) and the Crohn's Disease Endoscopic Index of Severity ...

      Known for Endoscopic Response | Crohns Disease | Mucosal Healing | Sescd Cdeis | Plr Nlr
      KOL-Index: 14807

      BACKGROUND & AIMS: Interleukin 23 contributes to the pathogenesis of ulcerative colitis (UC). We investigated the effects of mirikizumab, a monoclonal antibody against the p19 subunit of interleukin 23, in a phase 2 study of patients with UC.

      METHODS: We performed a trial of the efficacy and safety of mirikizumab in patients with moderate to severely active UC, enrolling patients from 14 countries from January 2016 through September 2017. Patients were randomly assigned to groups given ...

      Known for Ulcerative Colitis | Mirikizumab Patients | Monoclonal Antibodies | Clinical Remission | Rectal Bleeding

      Key People For Ulcerative Colitis

      Top KOLs in the world
      #1
      William J Sandborn∥
      ulcerative colitis inflammatory bowel disease certolizumab pegol
      #2
      JeanFr’ed’eric JeanFrederic
      ulcerative colitis inflammatory bowel disease ibd patients
      #3
      Stephen B Hanauer
      ulcerative colitis inflammatory bowel disease certolizumab pegol
      #4
      Rutgeerts RUTGEERTS
      ulcerative colitis crohns disease mucosal healing
      #5
      Severine ARA VERMEIRE
      ulcerative colitis inflammatory bowel disease mucosal healing
      #6
      Schreiber Schreiber
      ulcerative colitis inflammatory bowel disease certolizumab pegol

      Department of Gastroenterology, Amsterdam University Medical Centres, Amsterdam, The Netherlands | Department of Gastroenterology and Hepatology, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, Netherlands. | Amsterdam UMC, G

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.